Results 171 to 180 of about 1,319,694 (261)

Forensic Dating of Venous Thromboembolism: Advances in Histological, Immunohistochemical and Molecular Markers. [PDF]

Diagnostics (Basel)
Forzese E, Cianci V, Sapienza D, Pepe L, Fiorentino V, Ieni A, Gualniera P, Asmundo A, Mondello C.   +8 more
europepmc   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Therapeutic efficacy of artemether-lumefantrine and molecular markers of antimalarial resistance in Niger, 2022. [PDF]

Malar J
Laminou IM, Kabirou SM, Arzika II, Yahaya A, Ahmed J, Deme AB, Diallo MA, Ngom B, Gaye A, Sene A, Sow D, Coulibaly E, Bahari-Tohon Z, Sanoussi E, Koko D, Cavros I.   +15 more
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Novel Molecular Markers and Immune-Related Candidate Genes for Blackleg Resistance in Rapeseed: A Genome-Wide Analysis. [PDF]

Int J Mol Sci
Starosta E, Jamruszka T, Szwarc J, Bocianowski J, Grynia M, Niemann J.   +5 more
europepmc   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

Unraveling forensic timelines using molecular markers in Phormia regina maggots. [PDF]

PLoS Genet
Lin SH, Bellantuono AJ, Lopez K, Wells JD, DeGennaro M.   +4 more
europepmc   +1 more source

Spatial biology in cancer epigenetics

Molecular Oncology, EarlyView.
Spatial epigenomics combines molecular profiling with tissue architecture to reveal how gene regulation is organized within intact tissues. In cancer, these technologies uncover the mechanisms driving tumor heterogeneity and microenvironmental interactions, opening new opportunities for biomarker discovery and precision medicine.
Eva Crespo‐García, Manel Esteller
wiley   +1 more source

A review on molecular markers of <i>Plasmodium falciparum</i>. [PDF]

J Parasit Dis
Abebe W, Woldesenbet D.
europepmc   +1 more source